Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
复制标题
DOI：
10.1182/asheducation-2013.1.591
复制
发表时间：
2013-12-01
影响因子：
3
通讯作者：
Leonard, John P.
中科院分区：
文献类型：
--
作者：
Cerchietti, Leandro;Leonard, John P.
弥漫性大 B 细胞淋巴瘤是最常见的淋巴瘤亚型，大多数患者是可以治愈的。然而，淋巴瘤治疗中最大的未满足需求之一仍然是预防复发或难治性疾病的新方法。基因组分析提供了重要的预后信息，目前正在临床试验中用于开发新的治疗策略。然而，很明显，表观遗传改变提供了一系列额外的靶点，这些靶点可以进行药理学修饰，并为改善患者的治疗结果提供了巨大的潜力。对这一领域的进一步了解正在提供重要的新见解，目前正在临床环境中探索这些见解。去甲基化剂和破坏组蛋白修饰剂的药物正在早期临床试验中，并取得了有希望的结果，而其他针对表观遗传途径的方法正在积极的临床前和早期临床开发中。
Diffuse large B-cell lymphoma, the most common lymphoma subtype, is curable in the majority of patients. However, one of the greatest unmet needs in lymphoma treatment remains novel approaches to prevent relapsed or refractory disease. Genomic profiling has provided important prognostic information that is being used in the development of novel therapeutic strategies currently in clinical trials. It is clear, however, that epigenetic alterations provide an additional series of targets that can be pharmacologically modified and offer great potential to improving patient outcomes. Greater understanding of this area is providing important new insights that are now being explored in the clinical setting. Demethylating agents and drugs that disrupt histone modifiers are in early clinical trials with promising results, and other approaches targeting epigenetic pathways are in active preclinical and early clinical development.